Austin Private Wealth LLC Has $508,000 Stock Holdings in Pfizer Inc. (NYSE:PFE)

Austin Private Wealth LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 28.8% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 19,144 shares of the biopharmaceutical company’s stock after acquiring an additional 4,285 shares during the period. Austin Private Wealth LLC’s holdings in Pfizer were worth $508,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. GFS Advisors LLC bought a new position in shares of Pfizer in the fourth quarter valued at $12,841,000. Turtle Creek Wealth Advisors LLC raised its holdings in shares of Pfizer by 14.6% in the 4th quarter. Turtle Creek Wealth Advisors LLC now owns 10,394 shares of the biopharmaceutical company’s stock valued at $276,000 after purchasing an additional 1,326 shares during the period. TCI Wealth Advisors Inc. lifted its stake in Pfizer by 29.6% in the 4th quarter. TCI Wealth Advisors Inc. now owns 19,706 shares of the biopharmaceutical company’s stock valued at $523,000 after purchasing an additional 4,506 shares during the last quarter. Coastwise Capital Group LLC increased its position in Pfizer by 7.7% during the fourth quarter. Coastwise Capital Group LLC now owns 72,735 shares of the biopharmaceutical company’s stock worth $1,930,000 after buying an additional 5,172 shares during the last quarter. Finally, CMG Global Holdings LLC raised its stake in Pfizer by 19.1% in the fourth quarter. CMG Global Holdings LLC now owns 18,277 shares of the biopharmaceutical company’s stock valued at $475,000 after buying an additional 2,927 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of PFE stock opened at $26.51 on Friday. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The business has a fifty day simple moving average of $26.25 and a 200 day simple moving average of $27.89. The company has a market cap of $150.20 billion, a P/E ratio of 35.82, a P/E/G ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The company had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same period last year, the company posted ($0.17) EPS. On average, sell-side analysts forecast that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.49%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio is presently 232.44%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on PFE shares. UBS Group dropped their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Citigroup cut their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday. Truist Financial decreased their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Wednesday, October 23rd. Finally, Wolfe Research initiated coverage on Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.